WO1996013267A3 - Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome - Google Patents
Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome Download PDFInfo
- Publication number
- WO1996013267A3 WO1996013267A3 PCT/US1995/013624 US9513624W WO9613267A3 WO 1996013267 A3 WO1996013267 A3 WO 1996013267A3 US 9513624 W US9513624 W US 9513624W WO 9613267 A3 WO9613267 A3 WO 9613267A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- brimonidine
- glaucoma
- derivatives
- prostaglandins
- Prior art date
Links
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 229960003679 brimonidine Drugs 0.000 title abstract 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000000464 adrenergic agent Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des combinaisons d'agents adrénergiques alpha tels que la brimonidine et ses dérivés tels que représentés par la formule (I), dans laquelle chaque Y est choisi séparément dans le groupe consistant en N, N-CH3, O, S et C-R1; R1 représente hydrogène, oxo ou alkyle inférieur; R2, R3 et R4 sont choisis séparément dans le groupe consistant en hydrogène, halogène, alkyle inférieur et alcényle inférieur; n vaut un entier de 1 à 3; et une ligne en pointillés à côté d'une ligne pleine indique soit une liaison simple soit une liaison double, à condition que lorsque n=1, les deux liaisons entre Y et C-R1 ne puissent être des liaisons doubles, et des prostaglandines connues en soi utilisées pour induire une baisse de la pression intraoculaire. Ces combinaisons sont utiles dans des compositions, des méthodes de traitement et des articles produits, destinés au traitement du glaucome et à l'atténuation d'une pression intraoculaire élevée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33005094A | 1994-10-27 | 1994-10-27 | |
| US08/330,050 | 1994-10-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996013267A2 WO1996013267A2 (fr) | 1996-05-09 |
| WO1996013267A3 true WO1996013267A3 (fr) | 1996-07-04 |
Family
ID=23288106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/013624 WO1996013267A2 (fr) | 1994-10-27 | 1995-10-20 | Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1996013267A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| WO1998020881A1 (fr) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc | 15-cetal-prostaglandines pour le traitement du glaucome ou de l'hypertension oculaire |
| AU6545498A (en) | 1997-03-07 | 1998-09-22 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
| WO2004073708A1 (fr) * | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide et brimonidine pour le traitement d'etats oculaires |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| EP2329849B1 (fr) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
| RU2519676C1 (ru) | 2010-03-26 | 2014-06-20 | Галдерма Ресерч Энд Девелопмент | Усовершенствованные способы и композиции для безопасного и эффективного лечения эритемы |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| DK2444068T4 (en) | 2010-10-21 | 2018-03-05 | Galderma Sa | Brimonide sub-composition |
| PH12014500179A1 (en) * | 2011-07-20 | 2014-03-24 | Allergan Inc | Fixed dose combination of bimatoprost and brimonidine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008585A1 (fr) * | 1992-10-13 | 1994-04-28 | Alcon Laboratories, Inc. | Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome |
-
1995
- 1995-10-20 WO PCT/US1995/013624 patent/WO1996013267A2/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008585A1 (fr) * | 1992-10-13 | 1994-04-28 | Alcon Laboratories, Inc. | Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome |
Non-Patent Citations (1)
| Title |
|---|
| SERLE JB: "Pharmacological advances in the treatment of glaucoma.", DRUGS AGING, SEP 1994, 5 (3) P156-70, NEW ZEALAND * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996013267A2 (fr) | 1996-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996013267A3 (fr) | Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome | |
| EP1225168A3 (fr) | Dérivés de prostaglandines pour le traitement du glaucome et de l'hypertension oculaire | |
| TR200003844T2 (tr) | Epotilon türevleri, sentezleri ve kullanımları | |
| MY121967A (en) | New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency | |
| GEP20115347B (en) | Heterocyclocarboxamide derivatives | |
| IL157773A0 (en) | 2-amino-propanol derivatives | |
| BG103485A (en) | Ketobanzamides as calpain inhibitors | |
| MY113022A (en) | Novel pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present | |
| AU3192195A (en) | Thiazolidinedione derivatives, their production and use | |
| WO1996013259A3 (fr) | Procede et combinaisons servant a inhiber les proteine kinases | |
| IE893294L (en) | Piperidinyl benzimidazoles | |
| HU9503401D0 (en) | Novel 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives | |
| CA2221110A1 (fr) | Utilisation de derives d'acide cyclopentane heptan(ene)oique, 2-heteroarylalkenyle en tant qu'agents therapeutiques pour le traitement de l'hypertension oculaire | |
| WO2001058866A3 (fr) | Lipides oculaires hypoallergeniques | |
| TW427913B (en) | Eye drop composition comprising pilocarpine and a β-blocking agent and process making the same | |
| ATE160792T1 (de) | Oligomere, sterisch gehinderte polyamin-vernetzer und diese vernetzer enthaltende überzugsmasse | |
| MY132550A (en) | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists | |
| CA2048010A1 (fr) | Derives de la proline | |
| WO1999002532A3 (fr) | Composes polycycliques partiellement hydrogenes | |
| AU6597790A (en) | Use of 6- or 7-hydroxyindole derivatives as couplers and dyeing compositions and methods using these | |
| RU2001135821A (ru) | Состав для полости рта, содержащий перлит | |
| ATE345335T1 (de) | Acetale, ihre verwendung als riechstoffe und verfahren zu ihrer herstellung | |
| EP1121932A4 (fr) | Medicaments pour maladies oculaires | |
| MY111216A (en) | 2-hydroxy-3-[1-(1h-imidazol-4-yl)alkyl]-benzenecarboximidamides | |
| EP0355689A3 (fr) | Dérivés de pyrano [f] quinoline et compositions pharmaceutiques les contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |